innovations to accelerate vaccine development and manufacture

Inno4Vac is a public-private partnership that addresses scientific bottlenecks in vaccine development.

It proposes to develop predictive biological and mathematical models of vaccine performance and bio-manufacturing.

Artificial intelligence combined with big data and computational modelling will be used to build an open-access and cloud-based platform for in silico vaccine efficacy assessment and development. Controlled human infection models and cell-based human in vitro 3D models will be developed to enable early evaluation of vaccine efficacy and prediction of immune protection.

Finally, for vaccine bio-manufacturing the goal is to establish an open source in silico simulation platform for guiding the production of vaccine candidates and associated stability testing.

Pipetting Samples and Test Tube
Inno4Vac icon transparent_edited_edited.png

At a glance

innovations to accelerate vaccine development and manufacture

01/09/2021 to 28/02/2027
European Vaccine Initiative (EVI)
Innovative Medicines Initiative 2 (IMI2)
Public-private partnership
€ 38.5 M

(€18.6M IMI, €19.9M EFPIA)

Latest news